Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 3
1989 1
1992 3
1993 2
1994 9
1995 5
1996 4
1997 12
1998 3
1999 7
2000 5
2001 7
2002 11
2003 14
2004 12
2005 16
2006 18
2007 22
2008 29
2009 30
2010 33
2011 39
2012 25
2013 32
2014 42
2015 45
2016 48
2017 48
2018 53
2019 70
2020 76
2021 69
2022 91
2023 77
2024 68
2025 75

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

954 results

Results by year

Filters applied: . Clear all
Page 1
Central serous chorioretinopathy: An evidence-based treatment guideline.
Feenstra HMA, van Dijk EHC, Cheung CMG, Ohno-Matsui K, Lai TYY, Koizumi H, Larsen M, Querques G, Downes SM, Yzer S, Breazzano MP, Subhi Y, Tadayoni R, Priglinger SG, Pauleikhoff LJB, Lange CAK, Loewenstein A, Diederen RMH, Schlingemann RO, Hoyng CB, Chhablani JK, Holz FG, Sivaprasad S, Lotery AJ, Yannuzzi LA, Freund KB, Boon CJF. Feenstra HMA, et al. Among authors: holz fg. Prog Retin Eye Res. 2024 Jul;101:101236. doi: 10.1016/j.preteyeres.2024.101236. Epub 2024 Feb 1. Prog Retin Eye Res. 2024. PMID: 38301969 Free article. Review.
Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial.
Lanzetta P, Korobelnik JF, Heier JS, Leal S, Holz FG, Clark WL, Eichenbaum D, Iida T, Xiaodong S, Berliner AJ, Schulze A, Schmelter T, Schmidt-Ott U, Zhang X, Vitti R, Chu KW, Reed K, Rao R, Bhore R, Cheng Y, Sun W, Hirshberg B, Yancopoulos GD, Wong TY; PULSAR Investigators. Lanzetta P, et al. Among authors: holz fg. Lancet. 2024 Mar 23;403(10432):1141-1152. doi: 10.1016/S0140-6736(24)00063-1. Epub 2024 Mar 7. Lancet. 2024. PMID: 38461841 Clinical Trial.
Age-related macular degeneration.
Lim LS, Mitchell P, Seddon JM, Holz FG, Wong TY. Lim LS, et al. Among authors: holz fg. Lancet. 2012 May 5;379(9827):1728-38. doi: 10.1016/S0140-6736(12)60282-7. Lancet. 2012. PMID: 22559899 Review.
Central serous chorioretinopathy: Towards an evidence-based treatment guideline.
van Rijssen TJ, van Dijk EHC, Yzer S, Ohno-Matsui K, Keunen JEE, Schlingemann RO, Sivaprasad S, Querques G, Downes SM, Fauser S, Hoyng CB, Piccolino FC, Chhablani JK, Lai TYY, Lotery AJ, Larsen M, Holz FG, Freund KB, Yannuzzi LA, Boon CJF. van Rijssen TJ, et al. Among authors: holz fg. Prog Retin Eye Res. 2019 Nov;73:100770. doi: 10.1016/j.preteyeres.2019.07.003. Epub 2019 Jul 15. Prog Retin Eye Res. 2019. PMID: 31319157 Free article. Review.
Consensus Nomenclature for Reporting Neovascular Age-Related Macular Degeneration Data: Consensus on Neovascular Age-Related Macular Degeneration Nomenclature Study Group.
Spaide RF, Jaffe GJ, Sarraf D, Freund KB, Sadda SR, Staurenghi G, Waheed NK, Chakravarthy U, Rosenfeld PJ, Holz FG, Souied EH, Cohen SY, Querques G, Ohno-Matsui K, Boyer D, Gaudric A, Blodi B, Baumal CR, Li X, Coscas GJ, Brucker A, Singerman L, Luthert P, Schmitz-Valckenberg S, Schmidt-Erfurth U, Grossniklaus HE, Wilson DJ, Guymer R, Yannuzzi LA, Chew EY, Csaky K, Monés JM, Pauleikhoff D, Tadayoni R, Fujimoto J. Spaide RF, et al. Among authors: holz fg. Ophthalmology. 2020 May;127(5):616-636. doi: 10.1016/j.ophtha.2019.11.004. Epub 2019 Nov 14. Ophthalmology. 2020. PMID: 31864668 Free PMC article.
Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials.
Heier JS, Lad EM, Holz FG, Rosenfeld PJ, Guymer RH, Boyer D, Grossi F, Baumal CR, Korobelnik JF, Slakter JS, Waheed NK, Metlapally R, Pearce I, Steinle N, Francone AA, Hu A, Lally DR, Deschatelets P, Francois C, Bliss C, Staurenghi G, Monés J, Singh RP, Ribeiro R, Wykoff CC; OAKS and DERBY study investigators. Heier JS, et al. Among authors: holz fg. Lancet. 2023 Oct 21;402(10411):1434-1448. doi: 10.1016/S0140-6736(23)01520-9. Lancet. 2023. PMID: 37865470 Clinical Trial.
Reply.
Holz FG, Figueroa MS, Bandello F, Yang Y, Ohji M, Dai H, Wykrota H, Sharma S, Dunger-Baldauf C, Lacey S, Macfadden W, Mitchell P; all the LUMINOUS study investigators. Holz FG, et al. Retina. 2020 Sep;40(9):e51-e53. doi: 10.1097/IAE.0000000000002909. Retina. 2020. PMID: 32842092 No abstract available.
Pseudoxanthoma elasticum - Genetics, pathophysiology, and clinical presentation.
Pfau K, Lengyel I, Ossewaarde-van Norel J, van Leeuwen R, Risseeuw S, Leftheriotis G, Scholl HPN, Feltgen N, Holz FG, Pfau M. Pfau K, et al. Among authors: holz fg. Prog Retin Eye Res. 2024 Sep;102:101274. doi: 10.1016/j.preteyeres.2024.101274. Epub 2024 May 28. Prog Retin Eye Res. 2024. PMID: 38815804 Free PMC article. Review.
954 results